Ensuring the Long-Term Effectiveness of Clinical Trials

In a recent video interview with Applied Clinical Trials, Iddo Peleg, CEO and co-founder at Yonalink, discussed the impact of recent FDA and NIH actions on clinical trials. With changes in funding and DEI initiatives, there is a need to make trials more accessible for patients. Peleg highlighted how advancements in technology could address this, not only increasing accessibility, but efficiency as well.

ACT: Looking forward, what should stakeholders be focusing on to ensure their research and studies remain effective in the current climate of clinical research?

Peleg: I think now that we see more acceptance for new technologies, I think they need to ask themselves if what they did in the last 20 years or the last 25 years is still relevant. If you want to stay relevant, you need to think if you are relevant. It's not enough to say, “I'm going to do exactly what we did, not just four years ago, 10 years ago, and 20 years ago.” Because if we didn't change and you do clinical trials exactly the same as you did 20 years ago, something is broken. I think all the stakeholders, even the technology vendors, do you just do some type of different angle of the same technology, or do you truly want to disrupt and you truly want to bring efficiency, you want to bring innovation into clinical trials? For the stakeholders, the pharma, and CROs, they need to ask themselves if what I'm doing right now is something that can stay or I'm doing it just because someone before me did it exactly the same. This is a time for change, this is a time for disruption. If I may say, I hope that in the next few years, we will see the FDA starting to promote more efficiency and more adaptation of new technologies. This is the key. If we have more technologies, we will have more clinical trials, we will enroll more patients, and eventually we will have more new therapies in the market, and we can make clinical trials the care option for any American.